Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion
Launched by UNIVERSITY OF IOWA · Jul 12, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a method called thoracolumbar interfascial plane (TLIP) blocks to help manage pain and improve recovery in older adults undergoing spinal fusion surgery. The TLIP block involves using anesthesia to numb the area around the spine, which has been shown in earlier studies to reduce post-surgery pain. This study is focused on understanding how easy it is to recruit participants, gather feedback, and identify any challenges in using this technique. The goal is to collect information that will help plan a larger study to see how effective TLIP blocks are at reducing pain, improving mobility, and decreasing the use of opioids and the risk of delirium in older adults.
To be eligible for this study, participants must be 65 years or older and scheduled for elective lumbar spinal fusion surgery involving three or fewer vertebrae. They should not have severe heart or lung problems, cognitive issues like dementia, or other significant health conditions that could complicate the procedure. If participants join the study, they can expect to receive the TLIP block before their surgery and will be asked to provide feedback about their experience. This trial is currently recruiting participants and aims to improve pain management approaches for older adults undergoing back surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Are 65 or older
- • Indicated for lumbar spinal fusion of less than or equal to 3 levels
- • Undergoing elective surgery
- • no contraindications to local anesthetic or procedures
- • no severe cardiac or respiratory disease
- • no preexisting cognitive dysfunction/dementia
- Exclusion Criteria:
- • 64 years old and younger
- • emergency treatment
- • pathologic fractures
- • seeking revision surgery
- • major liver or kidney dysfunction
- • coexisting hematological disorder or irreversible abnormal coagulation
- • patients with previous diagnosis of dementia or SLUMS score \<20
- • patient unable to communicate/cooperate/language barrier
- • BMI\>40
- • allergy to study medications
- • opioid tolerant (oral opioid intake morphine equivalent =\< 60 mg/day)
- • other sources of chronic pain like fibromyalgia
- • patients with associated significant CNS or respiratory disease (home oxygen requirements)
- • incarcerated patients
- • psychiatric illnesses preoperative neurological deficits greater than one motor group, less than three out of five motor functions
- • pregnant or breast feeding
About University Of Iowa
The University of Iowa, a leading academic and research institution, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses the expertise of its faculty and researchers to investigate cutting-edge therapies and treatments across various medical fields. Committed to ethical research practices and patient-centered care, the University of Iowa strives to contribute significantly to medical knowledge and improve health outcomes through rigorous scientific inquiry and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Trial Officials
Catherine R Olinger, MD
Principal Investigator
Clinical Assistant Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials